Polarean Imaging Plc is a medical drug-devising company. The Company with its subsidiaries operates in the medical imaging market and develops equipment to enable existing magnetic resonance imaging (MRI) systems. The Company focuses on improving the level of pulmonary functional imaging, and specializing the use of polarised Xenon gas (129Xe) as an imaging agent to visualize ventilation, and gas exchange. The Group also develops and manufactures high performance MRI radiofrequency (RF) coils which are a required for imaging 129Xe in the MRI system. The United States food and drug administration (FDA) has accepted the group’s III clinical trial and design.